Sinocare Inc. (300298.SZ) develops, manufactures and markets blood glucose monitoring systems and other rapid diagnostic testing products for chronic disease management, primarily diabetes; core offerings include blood glucose meters such as the Gold AQ Plus series, Safe AQ Max series and One Sinocare series, test strips, uric acid meters including the UG series, EA-11 and UA-I models, glycated hemoglobin analyzers, blood pressure monitors, continuous glucose monitoring (CGM) systems like the iCan CGM, HbA1c testing systems and diabetes management software; the company also provides health management services and point-of-care testing solutions to patients and medical institutions.
Founded in 2002 and headquartered in Changsha, Hunan Province, China, Sinocare operates nine global research, development and manufacturing sites with presence in over 70 countries and regions, including strong market shares in China where it leads the blood glucose monitoring sector and ranks fourth worldwide; it serves retail, e-commerce, hospital and primary care channels targeting diabetes patients, healthcare professionals and chronic disease sufferers primarily in Asia, Europe, North America and other international markets.
Sinocare maintains subsidiaries including Sinocare Meditech Inc. and Trividia Health Inc., the latter resulting from its 2016 acquisitions of Nipro Diagnostics Inc. (renamed Trividia Health) and PTS Diagnostics Inc. to bolster its global blood glucose leadership; in 2024, the company completed the acquisition of Nipro Diagnostics and recently formed a strategic partnership with A. Menarini Diagnostics for exclusive distribution of its third-generation iCan CGM products across more than 20 European jurisdictions under a co-branded label, enhancing its expansion in Europe's growing CGM market.